<!DOCTYPE html>
<html>
<head>
    <style>
        .annotation-head {
            padding-top: 7px;
        }

        .annotation-segment, .annotation-head {
            position: relative;
        }

        .anno {
            position: relative;
            text-align: center;
        }

        .label {
            -webkit-border-radius: 3px;
            -moz-border-radius: 3px;
            border-radius: 3px;

            display: inline-block;
            padding: 2px 0;
            font-size: 11.844px;
            font-weight: bold;
            line-height: 14px;
            color: #000000;
            text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.25);
            white-space: nowrap;
            vertical-align: baseline;
            background-color: #999999;
        }

        .marker {
            background: lightgreen;
        }

        .collapsible {
            background-color: #929af0;
            color: #444;
            cursor: pointer;
            padding: 18px;
            width: 100%;
            border: none;
            text-align: left;
            outline: none;
            font-size: 15px;
        }

        .collapsible:hover {
            background-color: #ccc;
        }

        .midcontainer {
            overflow: hidden;
            overflow-x: auto;
            white-space: nowrap;
            margin: 10px;
        }
        .abstractcontainer {
            margin: 10px;
            line-height: 200%;
        }

        .supercontainer {
            border-style: solid;
	        border-width: 1px;
	        border-color: black;
        	border-radius: 3px;
            margin: 10px;
        }
    </style>
    <script src="http://ajax.googleapis.com/ajax/libs/jquery/1.4.1/jquery.min.js" type="text/javascript"></script>
    <script src="http://ajax.googleapis.com/ajax/libs/prototype/1.6.1.0/prototype.js" type="text/javascript"></script>
    <script src="http://ajax.googleapis.com/ajax/libs/scriptaculous/1.8.3/scriptaculous.js"
            type="text/javascript"></script>
    <script type="text/javascript">
        (function ($) {
            String.prototype.width = function (font) {

                var f = font || '12px arial',
                    o = $('<div>' + this + '</div>')
                        .css({
                            'position': 'absolute',
                            'float': 'left',
                            'white-space': 'nowrap',
                            'visibility': 'hidden',
                            'font': f
                        })
                        .appendTo($('body')),
                    w = o.width();

                o.remove();

                return w;
            }

            $(document).ready(function () {
                $('.container').each(function () {
                    var c = $(this);
                    $(c).find('.marker').each(function () {
                        var $t = $(this),
                            pos = $t.attr('data-anno-label'),
                            id = $t.attr('head-id'),
                            annoStr = pos;
                        var total_width = 0;
                        $(c).find('.annotation-head .anno').each(function () {
                            total_width += $(this).width();
                        })
                        // create an annotation for each marker
                        var top = this.offsetTop - 5,
                            left = this.offsetLeft - total_width,
                            width = $t.width(),
                            style = 'style="top:' + top + 'px; left:' + left + 'px;width:' + width + 'px;"';

                        $(c).find('.annotation-head').append('<span class="anno label" ' + style + '>' + annoStr + '</span>');
                    });
                })
            });
        })(jQuery);

    </script>
</head>

<body>


<button type="button" class="collapsible">AnnotatorA - AnnotatorB</button>
        <div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  The results suggest that rational therapy for severe CHF includes addition of the aldosterone antagonist  <span class="marker" data-anno-id="0" data-anno-label="P1">spironolactone</span>  to low doses of  <span class="marker" data-anno-id="1" data-anno-label="P1">captopril</span>  ( or another ACE inhibitor ) and high doses of loop diuretics , provided renal function is adequate . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  The results suggest that rational therapy for severe CHF includes addition of the aldosterone antagonist  <span class="marker" data-anno-id="0" data-anno-label="P1">spironolactone</span>  to low doses of  <span class="marker" data-anno-id="1" data-anno-label="P1">captopril</span>  ( or another ACE inhibitor ) and high doses of  <span class="marker" data-anno-id="2" data-anno-label="P1">loop diuretics</span>  , provided renal function is adequate . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Captopril and spironolactone therapy for refractory congestive heart failure.</u></h4>Short- and long-term clinical effects of the angiotensin-converting enzyme (ACE) inhibitor <b style='color:Tomato;'><i>captopril</i></b> in severe congestive heart failure (CHF) were evaluated during a 3-year open study of 124 inpatients with New York Heart Association (NYHA) functional class III or IV CHF refractory to treatment with cardiac glycosides and high doses of loop diuretics. <b style='color:Tomato;'><i>captopril</i></b> was added to each patient's regimen, which comprised combinations of <b style='color:Tomato;'><i>furosemide</i></b> (124 patients), digitalis (117 patients), and <b style='color:Tomato;'><i>spironolactone</i></b> (90 patients). By the end of the first month of <b style='color:Tomato;'><i>captopril</i></b> administration, improvement in NYHA functional class was seen in 89 patients (72%). During the first year of <b style='color:Tomato;'><i>captopril</i></b> treatment, the number of hospital admissions and hospital days declined significantly (p < 0.001) and functional class improved significantly (p < 0.001). Although most patients tolerated <b style='color:Tomato;'><i>captopril</i></b> well, 44% experienced hypotension, which in 10% of patients necessitated termination of <b style='color:Tomato;'><i>captopril</i></b> therapy. Although mean serum potassium levels tended to increase, serious hyperkalemia did not occur. After 1 year, a subset of 30 patients who had not initially received <b style='color:Tomato;'><i>spironolactone</i></b> deteriorated clinically and manifested increasing urinary aldosterone levels. Hypotension precluded increasing the <b style='color:Tomato;'><i>captopril</i></b> dose, but introduction of <b style='color:Tomato;'><i>spironolactone</i></b> improved clinical status in this cohort. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>rational</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>severe</i></b> <b style='color:DodgerBlue;'><i>CHF</i></b> <b style='color:DodgerBlue;'><i>includes</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>aldosterone</i></b> <b style='color:DodgerBlue;'><i>antagonist</i></b> <b style='color:MediumOrchid;'><i>spironolactone</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>low</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>captopril</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>another</i></b> <b style='color:DodgerBlue;'><i>ACE</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>loop</i></b> <b style='color:DodgerBlue;'><i>diuretics</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>provided</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>function</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>adequate</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  These findings may help clinicians identify patients for whom  <span class="marker" data-anno-id="0" data-anno-label="P1">acamprosate</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">naltrexone</span>  may be most beneficial . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  These findings may help clinicians identify patients for whom acamprosate and naltrexone may be most beneficial . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.</u></h4>The COMBINE study evaluated the effects of <b style='color:Tomato;'><i>acamprosate</i></b>, <b style='color:Tomato;'><i>naltrexone</i></b>, and the Combined Behavioral Intervention (CBI). In secondary analyses, our goals were to identify trajectories of any drinking prior to randomization, to characterize subjects in these trajectories, and to assess whether prerandomization trajectories predict drinking outcomes and moderate treatment response. ### methods We analyzed daily indicators of any drinking in 90 days prior to randomization using a trajectory-based approach. General linear models and generalized logistic regression assessed main and interactive effects of prerandomization drinking trajectories and treatment on summary drinking measures during active treatment. ### results We identified five trajectories of any drinking prior to randomization: "T1: frequent drinkers", "T2: very frequent drinkers", "T3: nearly daily drinkers", "T4: consistent daily drinkers", and "T5: daily drinkers stopping early". During treatment, "T3: nearly daily drinkers" and "T4: consistent daily drinkers" had significantly worse drinking outcomes than "T1: frequent drinkers", while "T5: daily drinkers stopping early" had comparable drinking outcomes to "T1: frequent drinkers". <b style='color:Tomato;'><i>acamprosate</i></b> significantly increased the chance of abstinence from heavy drinking for the "T2: very frequent drinking" trajectory but decreased the chance of abstinence from heavy drinking for "T5: daily drinkers stopping early". <b style='color:Tomato;'><i>naltrexone</i></b> differentially improved rates of continuous abstinence for very frequent drinkers. ### conclusions <b style='color:Tomato;'><i>acamprosate</i></b> benefited very frequent drinkers and contrary to expectations was associated with poorer response compared to placebo for consistent daily drinkers who had longer durations of pretreatment abstinence (e.g., ≥14 days). Baseline drinking trajectories also moderated <b style='color:Tomato;'><i>naltrexone</i></b> effects. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>findings</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>help</i></b> <b style='color:DodgerBlue;'><i>clinicians</i></b> <b style='color:DodgerBlue;'><i>identify</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>whom</i></b> <b style='color:MediumOrchid;'><i>acamprosate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>naltrexone</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>beneficial</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  The incidence of carcinoma , confirmed microscopically , was : control 14/20 ( 70 % ) ; high-dose gefitinib , 7/20 ( 35 % ) ; low-dose gefitinib , 7/20 ( 35 % ) ; high-dose meloxicam 7/21 ( 33 % ) ; and low-dose meloxicam , 12/20 ( 60 % ) . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  The incidence of carcinoma , confirmed microscopically , was : control 14/20 ( 70 % ) ; high-dose  <span class="marker" data-anno-id="0" data-anno-label="C1">gefitinib</span>  , 7/20 ( 35 % ) ; low-dose gefitinib , 7/20 ( 35 % ) ; high-dose  <span class="marker" data-anno-id="1" data-anno-label="C1">meloxicam</span>  7/21 ( 33 % ) ; and low-dose meloxicam , 12/20 ( 60 % ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis.</u></h4>To examine the chemopreventive effects of a selective cyclooxygenase (COX)-2 inhibitor, <b style='color:Tomato;'><i>meloxicam</i></b>, and a selective epidermal growth factor (EGF)-receptor tyrosine kinase inhibitor, <b style='color:Tomato;'><i>gefitinib</i></b> (as a single agent) on a carcinogen-induced rodent bladder carcinogenesis model. ### Materials And Methods The study comprised 103 male Fisher-344 rats (8 weeks old); after initial carcinogen treatment for 8 weeks with 0.05%N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in drinking water, the rats were divided into five groups, i.e. group 1, control (vehicle only); group 2, <b style='color:Tomato;'><i>gefitinib</i></b> high-dose (15 mg/kg by gavage once daily); group 3, <b style='color:Tomato;'><i>gefitinib</i></b> low-dose (5 mg/kg); group 4, <b style='color:Tomato;'><i>meloxicam</i></b> high-dose (1.8 mg/kg by gavage once daily); and group 5, <b style='color:Tomato;'><i>meloxicam</i></b> low-dose (0.6 mg/kg). Twelve weeks later the rats were killed; after fixing the bladder in 10% formalin, the number and size of hyperplasia and carcinoma foci were recorded microscopically in sections stained with haematoxylin and eosin, submitted entirely as multiple strips. ### results <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>incidence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>confirmed</i></b> <b style='color:DodgerBlue;'><i>microscopically</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>14/20</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>70</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:MediumOrchid;'><i>gefitinib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>7/20</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>low-dose</i></b> <b style='color:MediumOrchid;'><i>gefitinib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>7/20</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:MediumOrchid;'><i>meloxicam</i></b> <b style='color:DodgerBlue;'><i>7/21</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>33</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>low-dose</i></b> <b style='color:MediumOrchid;'><i>meloxicam</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>12/20</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>60</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The mean numbers of carcinomas per bladder in groups 1-5 were 1.2, 0.5, 0.4, 0.5 and 1.1, respectively. The incidence and the mean number of carcinomas per bladder were significantly lower in the treatment groups (P < 0.05) than in the control group, except in the low-dose <b style='color:Tomato;'><i>meloxicam</i></b> group. There were no significant adverse effects. ### conclusion Both <b style='color:Tomato;'><i>meloxicam</i></b> and <b style='color:Tomato;'><i>gefitinib</i></b> have inhibitory effects on rat bladder carcinogenesis with no significant adverse effects. A combination of these drugs would be worth studying for their synergistic effects.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  In this phase 3 trial , we randomly assigned ( in a 1:1:1 ratio ) patients with advanced renal cell carcinoma and no previous systemic therapy to receive  <span class="marker" data-anno-id="0" data-anno-label="P1">lenvatinib</span>  ( 20 mg orally once daily ) plus  <span class="marker" data-anno-id="1" data-anno-label="P1">pembrolizumab</span>  ( 200 mg intravenously once every 3 weeks ) ,  <span class="marker" data-anno-id="2" data-anno-label="N1">lenvatinib</span>  ( 18 mg orally once daily ) plus  <span class="marker" data-anno-id="3" data-anno-label="N1">everolimus</span>  ( 5 mg orally once daily ) , or sunitinib ( 50 mg orally once daily , alternating 4 weeks receiving treatment and 2 weeks without treatment ) . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  In this phase 3 trial , we randomly assigned ( in a 1:1:1 ratio ) patients with advanced renal cell carcinoma and no previous systemic therapy to receive  <span class="marker" data-anno-id="0" data-anno-label="P1">lenvatinib</span>  ( 20 mg orally once daily ) plus  <span class="marker" data-anno-id="1" data-anno-label="P1">pembrolizumab</span>  ( 200 mg intravenously once every 3 weeks ) ,  <span class="marker" data-anno-id="2" data-anno-label="P2">lenvatinib</span>  ( 18 mg orally once daily ) plus  <span class="marker" data-anno-id="3" data-anno-label="P2">everolimus</span>  ( 5 mg orally once daily ) , or sunitinib ( 50 mg orally once daily , alternating 4 weeks receiving treatment and 2 weeks without treatment ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.</u></h4><b style='color:Tomato;'><i>lenvatinib</i></b> in combination with <b style='color:Tomato;'><i>pembrolizumab</i></b> or <b style='color:Tomato;'><i>everolimus</i></b> has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of <b style='color:Tomato;'><i>sunitinib</i></b> is unclear. ### methods <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>randomly</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>1:1:1</i></b> <b style='color:DodgerBlue;'><i>ratio</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>previous</i></b> <b style='color:DodgerBlue;'><i>systemic</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:MediumOrchid;'><i>lenvatinib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>once</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>pembrolizumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>intravenously</i></b> <b style='color:DodgerBlue;'><i>once</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>lenvatinib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>18</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>once</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>everolimus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>once</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>once</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alternating</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary end point was progression-free survival, as assessed by an independent review committee in accordance with Response Evaluation Criteria in Solid Tumors, version 1.1. Overall survival and safety were also evaluated. ### results A total of 1069 patients were randomly assigned to receive <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>pembrolizumab</i></b> (355 patients), <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>everolimus</i></b> (357), or <b style='color:Tomato;'><i>sunitinib</i></b> (357). Progression-free survival was longer with <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>pembrolizumab</i></b> than with <b style='color:Tomato;'><i>sunitinib</i></b> (median, 23.9 vs. 9.2 months; hazard ratio for disease progression or death, 0.39; 95% confidence interval [CI], 0.32 to 0.49; P<0.001) and was longer with <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>everolimus</i></b> than with <b style='color:Tomato;'><i>sunitinib</i></b> (median, 14.7 vs. 9.2 months; hazard ratio, 0.65; 95% CI, 0.53 to 0.80; P<0.001). Overall survival was longer with <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>pembrolizumab</i></b> than with <b style='color:Tomato;'><i>sunitinib</i></b> (hazard ratio for death, 0.66; 95% CI, 0.49 to 0.88; P = 0.005) but was not longer with <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>everolimus</i></b> than with <b style='color:Tomato;'><i>sunitinib</i></b> (hazard ratio, 1.15; 95% CI, 0.88 to 1.50; P = 0.30). Grade 3 or higher adverse events emerged or worsened during treatment in 82.4% of the patients who received <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>pembrolizumab</i></b>, 83.1% of those who received <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>everolimus</i></b>, and 71.8% of those who received <b style='color:Tomato;'><i>sunitinib</i></b>. Grade 3 or higher adverse events occurring in at least 10% of the patients in any group included hypertension, diarrhea, and elevated lipase levels. ### conclusions <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>pembrolizumab</i></b> was associated with significantly longer progression-free survival and overall survival than <b style='color:Tomato;'><i>sunitinib</i></b>. (Funded by Eisai and Merck Sharp and Dohme; CLEAR ClinicalTrials.gov number, NCT02811861.).</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  A total of 164 patients with recurrent ovarian cancer were selected and randomly divided into two groups : experimental group ( n=82 ,  <span class="marker" data-anno-id="0" data-anno-label="P1">BEV</span>  +  <span class="marker" data-anno-id="1" data-anno-label="P1">paclitaxel</span>  +  <span class="marker" data-anno-id="2" data-anno-label="P1">carboplatin</span>  ) and control group ( n=82 , paclitaxel + carboplatin ) . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  A total of 164 patients with recurrent ovarian cancer were selected and randomly divided into two groups : experimental group ( n=82 ,  <span class="marker" data-anno-id="0" data-anno-label="P1">BEV</span>  +  <span class="marker" data-anno-id="1" data-anno-label="P1">paclitaxel</span>  +  <span class="marker" data-anno-id="2" data-anno-label="P1">carboplatin</span>  ) and control group ( n=82 ,  <span class="marker" data-anno-id="3" data-anno-label="C1">paclitaxel</span>  +  <span class="marker" data-anno-id="4" data-anno-label="C1">carboplatin</span>  ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Therapeutic effect of bevacizumab combined with paclitaxel and carboplatin on recurrent ovarian cancer.</u></h4>To observe the clinical efficacy and safety of <b style='color:Tomato;'><i>bevacizumab</i></b> (BEV) combined with <b style='color:Tomato;'><i>paclitaxel</i></b> on recurrent ovarian cancer. ### methods <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>164</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>recurrent</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>selected</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>randomly</i></b> <b style='color:DodgerBlue;'><i>divided</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>groups</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>experimental</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n=82</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>BEV</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n=82</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The clinical therapeutic effects including objective response rate (ORR), complete response (CR) rate, partial response (PR) rate, stable disease (SD), progressive disease (PD), progression free survival (PFS) and overall survival (OS) were evaluated, together with the adverse clinical reactions and improvement of quality of life (QoL). Immunohistochemistry was used to detect the expression of phosphate and tension homology deleted on chromosome ten (PTEN). ### results The PFS, OS and ORR of patients in the experimental group were significantly higher than those in the control group (p<0.05). In addition, the incidence rates of allergy, gastrointestinal reactions and leukopenia were significantly lower in the experimental group compared with those in the control group (p<0.05). There was no significant difference in QoL score between the two groups before treatment (p>0.05). However, after treatment, the QoL score in the experimental group was increased significantly compared with the control group (p<0.05). Moreover, the expression of PTEN in PR, SD and PD patients was lower, with significant difference between the two groups (p<0.05). ### conclusion The clinical therapeutic effect of BEV combined with <b style='color:Tomato;'><i>paclitaxel</i></b> in patients with recurrent ovarian cancer was improved, suggesting it might be beneficial for the treatment of ovarian cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  When rats were given  <span class="marker" data-anno-id="0" data-anno-label="C1">Li</span>  for 3 days , followed by a single injection of  <span class="marker" data-anno-id="1" data-anno-label="C1">imipramine</span>  , the concentrations of desipramine in the brain and serum were higher than those in the vehicle-treated rat , although the imipramine concentrations in both tissues did not differ in Li- and in vehicle-treated rats . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  When rats were given  <span class="marker" data-anno-id="0" data-anno-label="P1">Li</span>  for 3 days , followed by a single injection of  <span class="marker" data-anno-id="1" data-anno-label="P1">imipramine</span>  , the concentrations of desipramine in the brain and serum were higher than those in the vehicle-treated rat , although the imipramine concentrations in both tissues did not differ in Li- and in vehicle-treated rats . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effects of lithium on alterations of pharmacokinetics of imipramine and on the related changes of monoamines in rat brain.</u></h4>Rats were given chronically i.p. <b style='color:Tomato;'><i>imipramine</i></b> (20 mg/kg), LiCl (1 mg/kg) or both drugs to examine the effects of lithium (Li) on the alterations of <b style='color:Tomato;'><i>imipramine</i></b> pharmacokinetics in the whole brain and on the <b style='color:Tomato;'><i>imipramine</i></b>-related changes of nor<b style='color:Tomato;'><i>epinephrine</i></b> (NE) and serotonin (5-HT) levels in the brain. <b style='color:DodgerBlue;'><i>When</i></b> <b style='color:DodgerBlue;'><i>rats</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>Li</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>injection</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>imipramine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>desipramine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>brain</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>vehicle-treated</i></b> <b style='color:DodgerBlue;'><i>rat</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>although</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>imipramine</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>tissues</i></b> <b style='color:DodgerBlue;'><i>did</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>differ</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Li-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vehicle-treated</i></b> <b style='color:DodgerBlue;'><i>rats</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In rats receiving both drugs for 10 days, the steady state levels of <b style='color:Tomato;'><i>imipramine</i></b> and <b style='color:Tomato;'><i>desipramine</i></b> in the brain were the same as those in the vehicle-treated rats but the steady state level of <b style='color:Tomato;'><i>desipramine</i></b> was reached earlier with Li treatments presumably because of the enhanced demethylation of <b style='color:Tomato;'><i>imipramine</i></b>. Consequently, the <b style='color:Tomato;'><i>desipramine</i></b>-dependent alterations of NE and 3-methoxy-4-hydroxyphenylglycol levels in the brain appeared to be induced earlier and more markedly when Li was given simultaneously. As the 5-hydroxyindole acetic acid (5-HIAA) levels were elevated in the brains of Li-treated rats and reduced in brains of <b style='color:Tomato;'><i>imipramine</i></b>-treated rats as compared with the level in vehicle-treated rats, the 5-HIAA level in rats receiving both drugs was equivalent to that in vehicle-treated rats.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Drugs most commonly implicated in ADRs were amoxicillin + clavulanate ( 21.87 % ) followed by ceftriaxone ( 20.31 % ) . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Drugs most commonly implicated in ADRs were  <span class="marker" data-anno-id="0" data-anno-label="N1">amoxicillin</span>  +  <span class="marker" data-anno-id="1" data-anno-label="N1">clavulanate</span>  ( 21.87 % ) followed by ceftriaxone ( 20.31 % ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Adverse Drug Reactions in Hospitalized Pediatric Patients: A Prospective Observational Study.</u></h4>To determine the incidence, pattern, causality, preventability, severity and predictors of adverse drug reactions (ADRs) in pediatric population. ### methods It was a prospective, observational study that included patients of either sex, of any age treated in the pediatric wards of a tertiary care hospital. Study patients were followed throughout their hospital stay. Whenever an ADR was detected, all the required data was collected and analyzed. Data was analyzed for incidence, causality (by using WHO Probability scale and Naranjo's algorithm), preventability (by using Modified Shumock and Thornton scale), severity (by using Modified Hartwig and Siegel scale) and predictors of ADRs. ### results Of the 1775 children admitted in the pediatrics ward, 1082 patients met study criteria and were enrolled into the study. A total of 64 ADRs were identified from 54 patients. The incidence of ADRs was 4.99 %. Male patients experienced majority (68.52 %) of ADRs. <b style='color:DodgerBlue;'><i>Drugs</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>commonly</i></b> <b style='color:DodgerBlue;'><i>implicated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>ADRs</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>clavulanate</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>21.87</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>ceftriaxone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>20.31</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Most (51.56 %) of the ADRs reported belonged to the system organ class, gastrointestinal system disorders. Among the ADRs reported, 82.85 % of ADRs were mild. Majority (87.5 %) of the ADRs were of 'probable' causality category and 96.9 % were not preventable. There was a significant association between occurrence of ADRs and the use of ≥4 number of medications, age (infants) and gender (male). ### conclusions Among the pediatric population, infants, male gender and those receiving ≥4 number of medications are at risk of developing ADRs. Constant monitoring is required to address the safety issue in pediatric population especially in infants and patients receiving ≥4 drugs.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Combination therapy of  <span class="marker" data-anno-id="0" data-anno-label="P1">infliximab</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">methotrexate</span>  is more effective in reducing clinical and biochemical disease activity than gold with methylprednisolone treatment in RA patients during 22 weeks of treatment , especially in the first 6 weeks . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Combination therapy of  <span class="marker" data-anno-id="0" data-anno-label="P1">infliximab</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">methotrexate</span>  is more effective in reducing clinical and biochemical disease activity than  <span class="marker" data-anno-id="2" data-anno-label="C1">gold</span>  with  <span class="marker" data-anno-id="3" data-anno-label="C1">methylprednisolone</span>  treatment in RA patients during 22 weeks of treatment , especially in the first 6 weeks . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Analysis of efficacy and safety of multiple intravenous infusion of anti-tumor necrosis factor-alpha monoclonal antibody (Remicade) combined with methotrexate compared with sodium aurothiomalate and intramuscular depot methylprednisolone in rheumatoid arthritis].</u></h4>The objective of the paper was compare the effects and tolerability of combined therapy of multiple intravenous infusions of anti-tumour necrosis factor-alfa (TNF-alfa) monoclonal antibody (Remicade) with <b style='color:Tomato;'><i>methotrexate</i></b> versus treatment with sodium aurothiomalate and intramuscular depot <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b> in rheumatoid arthritis (RA). We investigate also the interval necessary to obtain the improvement in both treatment groups. 36 patients commencing intramuscular sodium aurothiomalate therapy with intramuscular depot <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b> acetate at weeks 0, 4, 8 and 12 in addition to chrysotherapy were compared in retrospective analysis with 32 patients starting with multiple intravenous infusions of <b style='color:Tomato;'><i>infliximab</i></b>, anti-TNF-alfa monoclonal antibody (Remicade) and <b style='color:Tomato;'><i>methotrexate</i></b> at a stable dose. Patients were assessed by composite clinical score (DAS 28) and C-reactive protein during 22 weeks of therapy. At week 2 and 6 a significantly greater percentage of <b style='color:Tomato;'><i>infliximab</i></b>-treated than gold-treated RA patients achieved improvement in each clinical measurement of disease activity. At 22 week of treatment moderate and good response according to EULAR criteria was achieved in 91% of <b style='color:Tomato;'><i>infliximab</i></b>-treated patients and 58% gold treated patients (p < 0.001). Adverse events were more frequently observed in <b style='color:Tomato;'><i>infliximab</i></b>-treated patients, but only gold-treated patients discontinued treatment because adverse events (2 patients due to proteinuria, 2 patients due to mucocutaneous changes and one patient due to leucopenia). The higher percentage of adverse events in <b style='color:Tomato;'><i>infliximab</i></b>-treated patients was caused mainly by the occurrence of infusion reactions (23 reactions out of 160 infusions); most of them were mild (somnolentia and headache) and transient. Viral infections (including herpes simplex and zoster) were more common in patients treated with <b style='color:Tomato;'><i>infliximab</i></b> and <b style='color:Tomato;'><i>methotrexate</i></b>. <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>infliximab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>reducing</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>biochemical</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>gold</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>RA</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>22</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>especially</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  In the second study 12 patients with small cell undifferentiated cancers were treated with  <span class="marker" data-anno-id="0" data-anno-label="N1">carboplatin</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="N1">etoposide</span>  and  <span class="marker" data-anno-id="2" data-anno-label="N1">ifosfamide</span>  . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  In the second study 12 patients with small cell undifferentiated cancers were treated with carboplatin , etoposide and ifosfamide . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.</u></h4>Two clinical studies were undertaken to study the toxicity profile and effects of interleukin-3 (rhIL-3) on chemotherapy-induced myelosuppression. Fifteen patients with recurrent ovarian carcinoma were treated with high dose <b style='color:Tomato;'><i>carboplatin</i></b> (800 mg m-2). All patients received 5.0 micrograms/kg/d rhIL-3 subcutaneously but timing and duration of rhIL-3 treatment differed. Constitutional symptoms were the major toxicity and in addition to the <b style='color:Tomato;'><i>carboplatin</i></b>-induced nausea and vomiting the combination was poorly tolerated. In 5/15 patients receiving high dose <b style='color:Tomato;'><i>carboplatin</i></b> rhIL-3 administration was discontinued due to nephrotoxicity (2 x), hypotension, severe malaise and bone pain. In this study, rhIL-3 ameliorated chemotherapy-induced neutropenia as well as thrombocytopenia and reduced the requirement for platelet transfusions in the second cycle of chemotherapy. However, rhIL-3 failed to prevent cumulative platelet toxicity. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>second</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>undifferentiated</i></b> <b style='color:DodgerBlue;'><i>cancers</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Three dose levels of rhIL-3 were explored (0.125, 5.0 and 7.5 micrograms/kg/d). In this study, toxicity of the treatment was mild, however, no beneficial haematologic effects of rhIL-3 could be demonstrated. In conclusion, the haematological effects of rhIL-3 were modest and dependent on the chemotherapeutic regimen, timing and duration of rhIL-3 treatment (in relation to the expected nadir). In general rhIL-3-induced toxicity was mild, but combination with high dose <b style='color:Tomato;'><i>carboplatin</i></b> could be hazardous if rhIL-3 is initiated at 24 h after the cytostatic agent.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Alternatively , it may be that the adverse effects of  <span class="marker" data-anno-id="0" data-anno-label="N1">pindolol</span>  and  <span class="marker" data-anno-id="1" data-anno-label="N1">propranolol</span>  are due to the simultaneous blockade of both beta 1- and beta 2-adrenoceptors . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Alternatively , it may be that the adverse effects of pindolol and propranolol are due to the simultaneous blockade of both beta 1- and beta 2-adrenoceptors . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Central propranolol and pindolol, but not atenolol nor metoprolol, inhibit sexual behavior in male rats.</u></h4>Are the anti-sexual effects of <b style='color:Tomato;'><i>propranolol</i></b> and <b style='color:Tomato;'><i>pindolol</i></b> due to actions within the brain? To answer this, these agents were administered directly into the brain ventricular system (ICV). Additionally, <b style='color:Tomato;'><i>atenolol</i></b> and <b style='color:Tomato;'><i>metoprolol</i></b> were evaluated to see whether differential delivery to the brain contributed to the observed lack of effect of systemically administered beta 1-adrenoceptor antagonists. ICV administration of <b style='color:Tomato;'><i>pindolol</i></b> (45 or 90 micrograms) was followed by a suppression of copulation. At 45 micrograms, inhibition was limited to performance aspects of copulation, whereas at 90 micrograms, decrements in motivational and performance aspects of copulation were evident. ICV administration of <b style='color:Tomato;'><i>propranolol</i></b> also suppressed copulatory behavior. At 45 micrograms, no significant effects were observed, whereas at 90 micrograms decrements in motivational and performance aspects of copulation were evident. In contrast, ICV administration of the beta 1-adrenoceptor antagonists, <b style='color:Tomato;'><i>atenolol</i></b> and <b style='color:Tomato;'><i>metoprolol</i></b>, was not associated with any major modifications in copulatory behavior. We suggest that the inhibitory effects of <b style='color:Tomato;'><i>propranolol</i></b> and <b style='color:Tomato;'><i>pindolol</i></b> may involve interactions with 5-HT1A receptors in the CNS. <b style='color:DodgerBlue;'><i>Alternatively</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>it</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>adverse</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>pindolol</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>simultaneous</i></b> <b style='color:DodgerBlue;'><i>blockade</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>beta</i></b> <b style='color:DodgerBlue;'><i>1-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>beta</i></b> <b style='color:DodgerBlue;'><i>2-adrenoceptors</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  3 . Systemic ( i.v . ) pretreatment with  <span class="marker" data-anno-id="0" data-anno-label="N1">furosemide</span>  ( 2 - 10 mg kg-1 ) increased urine volume and dose-dependently inhibited the pressor response to i.c.v .  <span class="marker" data-anno-id="1" data-anno-label="N1">clonidine</span>  ( 10 micrograms ) , and a long-lasting depressor response to clonidine was observed . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  3 . Systemic ( i.v . ) pretreatment with  <span class="marker" data-anno-id="0" data-anno-label="C1">furosemide</span>  ( 2 - 10 mg kg-1 ) increased urine volume and dose-dependently inhibited the pressor response to i.c.v .  <span class="marker" data-anno-id="1" data-anno-label="C1">clonidine</span>  ( 10 micrograms ) , and a long-lasting depressor response to clonidine was observed . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Furosemide inhibits the centrally-mediated pressor response to clonidine in conscious, normotensive rats.</u></h4>1. The effect of <b style='color:Tomato;'><i>furosemide</i></b> on the pressor response induced by intracerebroventricular (i.c.v.) injection of <b style='color:Tomato;'><i>clonidine</i></b> was investigated in freely moving, normotensive rats with chronically implanted arterial catheters. 2. When injected i.c.v., <b style='color:Tomato;'><i>clonidine</i></b> at doses of 5 and 10 micrograms produced a dose-dependent pressor response and a decrease in heart rate. No depressor response was induced by <b style='color:Tomato;'><i>clonidine</i></b>. <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>Systemic</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>pretreatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>furosemide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>kg-1</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>urine</i></b> <b style='color:DodgerBlue;'><i>volume</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>dose-dependently</i></b> <b style='color:DodgerBlue;'><i>inhibited</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pressor</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>i.c.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:MediumOrchid;'><i>clonidine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>micrograms</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>long-lasting</i></b> <b style='color:DodgerBlue;'><i>depressor</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>clonidine</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, <b style='color:Tomato;'><i>furosemide</i></b> treatment did not alter the bradycardia produced in response to <b style='color:Tomato;'><i>clonidine</i></b>. 4. The systemic treatment with <b style='color:Tomato;'><i>furosemide</i></b> (10 mg kg-1, i.v.) had no effect on the pressor response to i.v. noradrenaline. 5. These results suggest that reduction of body fluid volume inhibits the centrally-mediated pressor response to <b style='color:Tomato;'><i>clonidine</i></b> and leads to the hypotensive effect. We also suggest that combined treatment with a diuretic increases the hypotensive efficacy of <b style='color:Tomato;'><i>clonidine</i></b>.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  The differential effects of  <span class="marker" data-anno-id="0" data-anno-label="N1">haloperidol</span>  and  <span class="marker" data-anno-id="1" data-anno-label="N1">methamphetamine</span>  on time estimation in the rat . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  The differential effects of haloperidol and methamphetamine on time estimation in the rat . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>differential</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>haloperidol</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>methamphetamine</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>estimation</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>rat</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Forty rats were trained to make a left lever response if a signal (white noise) was 2.5s and to make a right lever response if the signal was 6.3s. When seven intermediate signal durations, to which responses were not reinforced, were randomly interspersed the probability of a right-lever ('long') response increased as a function of signal duration. <b style='color:Tomato;'><i>methamphetamine</i></b> shifted this psychometric function leftward and decreased its slope: <b style='color:Tomato;'><i>haloperidol</i></b> also decreased the slope but shifted the function rightward. A combination of <b style='color:Tomato;'><i>haloperidol</i></b> and <b style='color:Tomato;'><i>methamphetamine</i></b> led to a function similar to the saline control function. The leftward shift probably reflects an increase in the speed of an internal clock, and the rightward shift probably reflects a decrease in its speed. Since <b style='color:Tomato;'><i>methamphetamine</i></b> releases several catecholamines, including dopamine, and <b style='color:Tomato;'><i>haloperidol</i></b> blocks dopamine receptors, it is plausible that the horizontal location of the psychometric function (the speed of the clock) is related to the effective level of dopamine.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Patients with incurable cancer causing chronic pain rated above 6/10 on a numerical scale while receiving high-dose opioid therapy ( more than 200 mg/d of oral morphine equivalent ) and/or exhibiting severe opioid-related adverse events received intrathecal infusions of  <span class="marker" data-anno-id="0" data-anno-label="N1">ziconotide</span>  combined with  <span class="marker" data-anno-id="1" data-anno-label="N1">morphine</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="N1">ropivacaine</span>  , and  <span class="marker" data-anno-id="3" data-anno-label="N1">clonidine</span>  . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Patients with incurable cancer causing chronic pain rated above 6/10 on a numerical scale while receiving high-dose opioid therapy ( more than 200 mg/d of oral morphine equivalent ) and/or exhibiting severe opioid-related adverse events received intrathecal infusions of ziconotide combined with morphine , ropivacaine , and clonidine . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol.</u></h4>Ziconotide is a new analgesic agent administered intrathecally. It is challenging to use and can induce several and sometimes serious adverse events. A low initial dosage followed by slow titration may reduce serious adverse events. ### objective To determine whether a low starting dosage of ziconotide, followed by slow titration, decreases the incidence of major adverse events associated with ziconotide when used for intractable cancer pain. ### Study Design Observational cohort study. ### setting Three French cancer centers. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>incurable</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>causing</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>rated</i></b> <b style='color:DodgerBlue;'><i>above</i></b> <b style='color:DodgerBlue;'><i>6/10</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>numerical</i></b> <b style='color:DodgerBlue;'><i>scale</i></b> <b style='color:DodgerBlue;'><i>while</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>opioid</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg/d</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>morphine</i></b> <b style='color:DodgerBlue;'><i>equivalent</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and/or</i></b> <b style='color:DodgerBlue;'><i>exhibiting</i></b> <b style='color:DodgerBlue;'><i>severe</i></b> <b style='color:DodgerBlue;'><i>opioid-related</i></b> <b style='color:DodgerBlue;'><i>adverse</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>intrathecal</i></b> <b style='color:DodgerBlue;'><i>infusions</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>ziconotide</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>morphine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ropivacaine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clonidine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Seventy-seven patients were included. Adverse events were recorded in 57% of them; moderate adverse events occurred in 51%. Adverse events required treatment discontinuation in 7  (9%) including 5  (6%) for whom a causal role for ziconotide was highly likely; among them 4  (5%) were serious. All patients experienced a significant and lasting decrease in pain intensity  (by 48%) in response to intrathecal analgesic therapy that included ziconotide. ### limitations Limitations include the nonrandomized, observational nature of the study. Determining the relative contributions of each drug to adverse events was difficult, and some of the adverse events manifested as clinical symptoms of a subjective nature. ### conclusions The rates of minor and moderate adverse events were consistent with previous reports. However, the rate of serious adverse events was substantially lower. Our study confirms the efficacy of intrathecal analgesia with ziconotide for relieving refractory cancer pain. These results indicate that multimodal intrathecal analgesia in patients with cancer pain should include ziconotide from the outset in order to provide time for subsequent slow titration.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  The MBCs were 1 to 2 tubes higher than the broth dilution MICs for levofloxacin , 1 to 3 tubes higher than the broth dilution MICs for ofloxacin , 1 to 3 tubes higher than the broth dilution MICs for erythromycin , and the same as the broth dilution MICs for rifampin . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  The MBCs were 1 to 2 tubes higher than the broth dilution MICs for  <span class="marker" data-anno-id="0" data-anno-label="N1/P1">levofloxacin</span>  , 1 to 3 tubes higher than the broth dilution MICs for ofloxacin , 1 to 3 tubes higher than the broth dilution MICs for  <span class="marker" data-anno-id="1" data-anno-label="N1">erythromycin</span>  , and the same as the broth dilution MICs for  <span class="marker" data-anno-id="2" data-anno-label="P1">rifampin</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila.</u></h4>The susceptibilities of 56 Legionella pneumophila isolates (43 clinical and 15 environmental isolates) to <b style='color:Tomato;'><i>levofloxacin</i></b>, ofloxacin, <b style='color:Tomato;'><i>erythromycin</i></b>, and <b style='color:Tomato;'><i>rifampin</i></b> were studied with buffered charcoal yeast extract (BCYE) agar (inoculum, 10(4) CFU per spot), and the susceptibilities of five isolates were studied with buffered yeast extract (BYE) broth (inoculum, 10(5) CFU/ml). The MICs inhibiting 90% of strains tested on BCYE agar were 0.125, 0.25, 1.0, and < or = 0.004 micrograms/ml for <b style='color:Tomato;'><i>levofloxacin</i></b>, ofloxacin, <b style='color:Tomato;'><i>erythromycin</i></b>, and <b style='color:Tomato;'><i>rifampin</i></b>, respectively. The MICs by the BYE broth dilution method were 1 to 3, 2, 1 to 2, and 1 tube lower than those by the agar dilution method for <b style='color:Tomato;'><i>levofloxacin</i></b>, ofloxacin, <b style='color:Tomato;'><i>erythromycin</i></b>, and <b style='color:Tomato;'><i>rifampin</i></b>, respectively. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>MBCs</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>tubes</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>broth</i></b> <b style='color:DodgerBlue;'><i>dilution</i></b> <b style='color:DodgerBlue;'><i>MICs</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>levofloxacin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>tubes</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>broth</i></b> <b style='color:DodgerBlue;'><i>dilution</i></b> <b style='color:DodgerBlue;'><i>MICs</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>ofloxacin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>tubes</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>broth</i></b> <b style='color:DodgerBlue;'><i>dilution</i></b> <b style='color:DodgerBlue;'><i>MICs</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>erythromycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>same</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>broth</i></b> <b style='color:DodgerBlue;'><i>dilution</i></b> <b style='color:DodgerBlue;'><i>MICs</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>rifampin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In kinetic time-kill curve studies, at drug concentrations of 1.0 and 2.0 times the MIC, the most active drugs were <b style='color:Tomato;'><i>levofloxacin</i></b> and <b style='color:Tomato;'><i>rifampin</i></b>. At 72 h, concentrations of <b style='color:Tomato;'><i>levofloxacin</i></b> and <b style='color:Tomato;'><i>rifampin</i></b> of 2.0 times the MIC demonstrated a bactericidal effect against L. pneumophila. In contrast, at concentrations of 1.0 and 2.0 times the MICs regrowth was observed with ofloxacin and only a gradual decrease in the numbers of CFU per milliliter was observed with <b style='color:Tomato;'><i>erythromycin</i></b>. Only a minor inhibitory effect was observed with 0.25 or 0.5 time the MICs of all drugs at 24 to 48 h, with regrowth occurring at 72 h. In contrast to <b style='color:Tomato;'><i>erythromycin</i></b> or ofloxacin plus <b style='color:Tomato;'><i>rifampin</i></b> at 0.25 time the MICs, only <b style='color:Tomato;'><i>levofloxacin</i></b> plus <b style='color:Tomato;'><i>rifampin</i></b> demonstrated synergy. Thus, <b style='color:Tomato;'><i>levofloxacin</i></b> demonstrated the best inhibitory and bactericidal effects against L. pneumophila when it was studied alone or in a combination with <b style='color:Tomato;'><i>rifampin</i></b>.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1/P2/P3">Fluvoxamine</span>  is a fairly potent inhibitor of CYP2C19 and it has the potential for causing drug-drug interactions with substrates for CYP2C19 such as  <span class="marker" data-anno-id="1" data-anno-label="P1">imipramine</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P2">clomipramine</span>  ,  <span class="marker" data-anno-id="3" data-anno-label="P3">amitriptyline</span>  and diazepam . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  <span class="marker" data-anno-id="0" data-anno-label="C1/C2/C3">Fluvoxamine</span>  is a fairly potent inhibitor of CYP2C19 and it has the potential for causing drug-drug interactions with substrates for CYP2C19 such as  <span class="marker" data-anno-id="1" data-anno-label="C1">imipramine</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="C2">clomipramine</span>  ,  <span class="marker" data-anno-id="3" data-anno-label="C3">amitriptyline</span>  and diazepam . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro.</u></h4>The potent CYP1A2 inhibitor <b style='color:Tomato;'><i>fluvoxamine</i></b> has recently been shown also to be an effective inhibitor of the CYP2C19-mediated metabolism of the antimalarial drug <b style='color:Tomato;'><i>proguanil</i></b> in vivo. The purpose of the present study was to confirm this interaction in vitro. ### methods A high-performance liquid chromatography (HPLC) method was developed to assay 4-chlorophenylbiguanide (4-CPBG) and cycloguanil formed from <b style='color:Tomato;'><i>proguanil</i></b> by microsomes prepared from human liver. The limit of detection was 0.08 nmol mg-'. h-I. ### results The formation of 4-CPBG and cycloguanil could be described by one-enzyme kinetics, indicating that the formation of the two metabolites is almost exclusively catalysed by a single enzyme, i.e. CYP2C19 within the concentration range used, or that the contribution of an alternative low-affinity enzyme, probably CYP3A4, is very low. This notion was confirmed by the lack of potent inhibition by four CYP3A4 inhibitors: <b style='color:Tomato;'><i>ketoconazole</i></b>, <b style='color:Tomato;'><i>bromocriptine</i></b>, midazolam and dihydroergotamine. <b style='color:Tomato;'><i>fluvoxamine</i></b> was a very effective inhibitor of the oxidation of <b style='color:Tomato;'><i>proguanil</i></b>, displaying Ki values of 0.69 micromol x l(-1) for the inhibition of cycloguanil formation and 4.7 micromol x l(-1) for the inhibition of 4-CPBG formation. As expected, the CYP2C19 substrate <b style='color:Tomato;'><i>omeprazole</i></b> inhibited the formation of both metabolites with an IC50 of 10 micromol x l(-1). Nor<b style='color:Tomato;'><i>fluoxetine</i></b> and <b style='color:Tomato;'><i>sulfaphenazole</i></b> inhibited <b style='color:Tomato;'><i>proguanil</i></b> oxidation with Ki values of 7.3-16 micromol x l(-1), suggesting that the two compounds are moderate inhibitors of CYP2C19. ### conclusions <b style='color:MediumOrchid;'><i>Fluvoxamine</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>fairly</i></b> <b style='color:DodgerBlue;'><i>potent</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>CYP2C19</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>it</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>potential</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>causing</i></b> <b style='color:DodgerBlue;'><i>drug-drug</i></b> <b style='color:DodgerBlue;'><i>interactions</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>substrates</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>CYP2C19</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>imipramine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clomipramine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>amitriptyline</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>diazepam</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The combination of <b style='color:Tomato;'><i>fluvoxamine</i></b> and <b style='color:Tomato;'><i>proguanil</i></b> can not be recommended.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  The relative analgesic potency ratios were 0.65 ( 0.56 - 0.76 ) for  <span class="marker" data-anno-id="0" data-anno-label="C1">ropivacaine</span>  :  <span class="marker" data-anno-id="1" data-anno-label="C1">bupivacaine</span>  , 0.80 ( 0.70 - 0.92 ) for  <span class="marker" data-anno-id="2" data-anno-label="C2">ropivacaine</span>  :  <span class="marker" data-anno-id="3" data-anno-label="C2">levobupivacaine</span>  , and 0.81 ( 0.69 - 0.94 ) for  <span class="marker" data-anno-id="4" data-anno-label="C3">levobupivacaine</span>  :  <span class="marker" data-anno-id="5" data-anno-label="C3">bupivacaine</span>  . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  The relative analgesic potency ratios were 0.65 ( 0.56 - 0.76 ) for ropivacaine : bupivacaine , 0.80 ( 0.70 - 0.92 ) for ropivacaine : levobupivacaine , and 0.81 ( 0.69 - 0.94 ) for levobupivacaine : bupivacaine . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Minimum local analgesic doses of ropivacaine, levobupivacaine, and bupivacaine for intrathecal labor analgesia.</u></h4>Doses for intrathecal opioid-local anesthetic mixtures have been arbitrarily chosen. The aim of this study was to compare the analgesic efficacies of intrathecal <b style='color:Tomato;'><i>ropivacaine</i></b>, levo<b style='color:Tomato;'><i>bupivacaine</i></b>, and <b style='color:Tomato;'><i>bupivacaine</i></b> for labor analgesia and to determine the analgesic potency ratios for these three drugs. For this purpose, the authors used the up-down sequential allocation model, which estimates the minimum local analgesic dose for intrathecal local anesthetic. ### methods Ninety-seven nulliparous term parturients in spontaneous labor, requesting combined spinal-epidural analgesia, were randomly allocated to one of three groups to receive 0.25% spinal <b style='color:Tomato;'><i>ropivacaine</i></b>, levo<b style='color:Tomato;'><i>bupivacaine</i></b>, or <b style='color:Tomato;'><i>bupivacaine</i></b>. The initial dose of the local anesthetic drug was chosen to be 2.5 mg, and the testing interval was set at 0.25 mg. The subsequent doses were determined by the response of the previous parturient. Efficacy was accepted if the visual analog pain score decreased to 10 mm or less on a 100-mm scale within 30 min. The minimum local analgesic dose was calculated using the method of Dixon and Massey. ### results The intrathecal minimum local analgesic dose was 3.64 mg (95% confidence interval, 3.33-3.96 mg) for <b style='color:Tomato;'><i>ropivacaine</i></b>, 2.94 (2.73-3.16) mg for levo<b style='color:Tomato;'><i>bupivacaine</i></b>, and 2.37 (2.17-2.58) mg for <b style='color:Tomato;'><i>bupivacaine</i></b>. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>relative</i></b> <b style='color:DodgerBlue;'><i>analgesic</i></b> <b style='color:DodgerBlue;'><i>potency</i></b> <b style='color:DodgerBlue;'><i>ratios</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>0.65</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0.56</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>0.76</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>ropivacaine</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>bupivacaine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>0.80</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0.70</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>0.92</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>ropivacaine</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>levobupivacaine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>0.81</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0.69</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>0.94</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>levobupivacaine</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>bupivacaine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> There were significant trends (P </= 0.021) for greater motor block with <b style='color:Tomato;'><i>bupivacaine</i></b> and levo<b style='color:Tomato;'><i>bupivacaine</i></b>. ### conclusions This study suggests a potency hierarchy of spinal <b style='color:Tomato;'><i>bupivacaine</i></b> > levo<b style='color:Tomato;'><i>bupivacaine</i></b> > <b style='color:Tomato;'><i>ropivacaine</i></b>.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Additional results from MTT cell viability assays demonstrated that H1975 cell proliferation was not significantly decreased after Wnt inhibition by  <span class="marker" data-anno-id="0" data-anno-label="P1/P2">XAV939</span>  , but combination treatment with  <span class="marker" data-anno-id="1" data-anno-label="P1">everolimus</span>  ( mTOR inhibitor ) and  <span class="marker" data-anno-id="2" data-anno-label="P2">erlotinib</span>  resulted in synergistic cell growth inhibition . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Additional results from MTT cell viability assays demonstrated that H1975 cell proliferation was not significantly decreased after Wnt inhibition by XAV939 , but combination treatment with  <span class="marker" data-anno-id="0" data-anno-label="P1">everolimus</span>  ( mTOR inhibitor ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">erlotinib</span>  resulted in synergistic cell growth inhibition . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.</u></h4>Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when administered individually or in combination to non-small cell lung cancer (NSCLC) patients. However, the overall efficacies of TKIs are limited due to the development of drug resistance. Therefore, it is important to elucidate mechanisms of EGFR and c-Met TKI resistance in order to develop more effective therapies. Model NSCLC cell lines H1975 and H2170 were used to study the similarities and differences in mechanisms of EGFR/c-Met TKI resistance. H1975 cells are positive for the T790M EGFR mutation, which confers resistance to current EGFR TKI therapies, while H2170 cells are EGFR wild-type. Previously, H2170 cells were made resistant to the EGFR TKI <b style='color:Tomato;'><i>erlotinib</i></b> and the c-Met TKI SU11274 by exposure to progressively increasing concentrations of TKIs. In H2170 and H1975 TKI-resistant cells, key Wnt and mTOR proteins were found to be differentially modulated. Wnt signaling transducer, active β-catenin was upregulated in TKI-resistant H2170 cells when compared to parental cells. GATA-6, a transcriptional activator of Wnt, was also found to be upregulated in resistant H2170 cells. In H2170 <b style='color:Tomato;'><i>erlotinib</i></b> resistant cells, upregulation of inactive GSK3β (p-GSK3β) was observed, indicating activation of Wnt and mTOR pathways which are otherwise inhibited by its active form. However, in H1975 cells, Wnt modulators such as active β-catenin, GATA-6 and p-GSK3β were downregulated. <b style='color:DodgerBlue;'><i>Additional</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>MTT</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>viability</i></b> <b style='color:DodgerBlue;'><i>assays</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>H1975</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>proliferation</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>decreased</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>Wnt</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>XAV939</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>everolimus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>mTOR</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>erlotinib</i></b> <b style='color:DodgerBlue;'><i>resulted</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Thus, in H2170 cells and H1975 cells, simultaneous inhibition of key Wnt or mTOR pathway proteins in addition to EGFR and c-Met may be a promising strategy for overcoming EGFR and c-Met TKI resistance in NSCLC patients.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Profiling of drug-metabolizing enzymes/transporters in CD33 + acute myeloid leukemia patients treated with  <span class="marker" data-anno-id="0" data-anno-label="C1">Gemtuzumab-Ozogamicin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">Fludarabine</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="C1">Cytarabine</span>  and  <span class="marker" data-anno-id="3" data-anno-label="C1">Idarubicin</span>  . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Profiling of drug-metabolizing enzymes/transporters in CD33 + acute myeloid leukemia patients treated with  <span class="marker" data-anno-id="0" data-anno-label="P1">Gemtuzumab-Ozogamicin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">Fludarabine</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P1">Cytarabine</span>  and  <span class="marker" data-anno-id="3" data-anno-label="P1">Idarubicin</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Profiling</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>drug-metabolizing</i></b> <b style='color:DodgerBlue;'><i>enzymes/transporters</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>CD33</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>myeloid</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>Gemtuzumab-Ozogamicin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Fludarabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>Cytarabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Idarubicin</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Genetic heterogeneity in drug-metabolizing enzyme/transporter (DMET) genes affects specific drug-related cancer phenotypes. To investigate the relationships between genetic variation and response to treatment in acute myeloid leukemia (AML), we genotyped 1931 variants on DMET genes in 94 CD33-positive AML patients enrolled in a phase III multicenter clinical trial combining Gemtuzumab-<b style='color:Tomato;'><i>ozogamicin</i></b> (GO) with <b style='color:Tomato;'><i>fludarabine</i></b>-<b style='color:Tomato;'><i>cytarabine</i></b>-<b style='color:Tomato;'><i>idarubicin</i></b> (FLAI) regimen, with the DMET Plus platform. Two ADH1A variants showed statistically significant differences (odds ratio (OR)=5.68, P=0.0006; OR=5.35, P=0.0009) in allele frequencies between patients in complete/partial remission and patients without response, two substitutions on CYP2E1 (OR=0.13, P=0.001; OR=0.09, P=0.003) and one on SLCO1B1 (OR=4.68, P=0.002) were found to differently influence liver toxicity, and two nucleotide changes on SULTB1 and SLC22A12 genes correlated with response to GO (OR=0.24, P=0.0009; OR=2.75, P=0.0029). Genetic variants were thus found for the first time to be potentially associated with differential response and toxicity in AML patients treated with a combination of GO-FLAI regimen.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  The addition of trastuzumab , pertuzumab , bevacizumab , or lapatinib to chemotherapy significantly ( P < .05 ) improved objective response rate ( ORR ) , time to failure ( TTF ) , and overall survival ( OS ) in patients with HER2-positive ( HER2(+ ) ) disease . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  The addition of  <span class="marker" data-anno-id="0" data-anno-label="P1">trastuzumab</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P2">pertuzumab</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P3">bevacizumab</span>  , or lapatinib to  <span class="marker" data-anno-id="3" data-anno-label="P1/P2/P3">chemotherapy</span>  significantly ( P < .05 ) improved objective response rate ( ORR ) , time to failure ( TTF ) , and overall survival ( OS ) in patients with HER2-positive ( HER2(+ ) ) disease . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.</u></h4>Breast cancer is the most common cancer and the most frequent cause of death in women. Targeted therapies offer a possibility of effective and individualized therapy based on the molecular profile of the tumor. The aim of this systematic review was to evaluate the efficacy and safety of targeted agents added to chemotherapy or endocrine therapy in patients with previously untreated metastatic breast cancer (MBC) depending on their human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status (positive or negative). The systematic literature search was performed in PubMed, EMBASE, and the Cochrane Library to identify randomized controlled trials (RCTs). Thirteen trials were included. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>pertuzumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>lapatinib</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>P</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>.05</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>improved</i></b> <b style='color:DodgerBlue;'><i>objective</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ORR</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>failure</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TTF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>overall</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>OS</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HER2(+</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>trastuzumab</i></b> or <b style='color:Tomato;'><i>lapatinib</i></b> combined with endocrine therapy significantly (P < .05) improved ORR, time to progression (TTP), and progression-free survival (PFS) in patients with HER2(+) and HR(+) disease. In patients with HER2-negative (HER2(-)) cancer, <b style='color:Tomato;'><i>bevacizumab</i></b> or <b style='color:Tomato;'><i>lapatinib</i></b> added to chemotherapy significantly (P < .05), improved ORR but did not prolong PFS and OS (P > .05). In patients with HER2(-) and HR(-) disease, <b style='color:Tomato;'><i>trastuzumab</i></b> combined with chemotherapy did not significantly improve (P > .05) ORR or PFS. Targeted therapies also increased the overall risk of adverse events. So far, there is a lack of published results for <b style='color:Tomato;'><i>everolimus</i></b> and <b style='color:Tomato;'><i>trastuzumab</i></b> <b style='color:Tomato;'><i>emtansine</i></b> trials in patients with previously untreated MBC. The addition of targeted therapy to chemotherapy or endocrine therapy using HER2 and HR status significantly improved ORR, PFS, and OS in patients with previously untreated MBC.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Two of nine patients received 15 mg/kg  <span class="marker" data-anno-id="0" data-anno-label="P1">bevacizumab</span>  IV , 90 mg/m(2 )  <span class="marker" data-anno-id="1" data-anno-label="P1">irinotecan</span>  orally for five consecutive days , 100 mg/m(2)/day  <span class="marker" data-anno-id="2" data-anno-label="P1">temozolomide</span>  IV for 5 days , and 1.5 mg/m(2 )  <span class="marker" data-anno-id="3" data-anno-label="P1">vincristine</span>  IV , each administered every 21 days . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Two of nine patients received 15 mg/kg  <span class="marker" data-anno-id="0" data-anno-label="P1">bevacizumab</span>  IV , 90 mg/m(2 )  <span class="marker" data-anno-id="1" data-anno-label="P1">irinotecan</span>  orally for five consecutive days , 100 mg/m(2)/day  <span class="marker" data-anno-id="2" data-anno-label="P1">temozolomide</span>  IV for 5 days , and 1.5 mg/m(2 ) vincristine IV , each administered every 21 days . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.</u></h4>Chemotherapy for relapsed medulloblastoma has been inadequate, and most patients succumb to disease. ### methods We retrospectively reviewed nine cases of relapsed medulloblastoma treated with <b style='color:Tomato;'><i>bevacizumab</i></b>, <b style='color:Tomato;'><i>irinotecan</i></b>, ± <b style='color:Tomato;'><i>temozolomide</i></b>. Patients received one to three prior therapeutic regimens. Five patients received 10 mg/kg <b style='color:Tomato;'><i>bevacizumab</i></b> and 125-150 mg/m(2) <b style='color:Tomato;'><i>irinotecan</i></b> IV every 2 weeks, with <b style='color:Tomato;'><i>temozolomide</i></b>, starting at a median dose of 150 mg/m(2) orally for 5 days monthly. Two patients received <b style='color:Tomato;'><i>bevacizumab</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b>, but not <b style='color:Tomato;'><i>temozolomide</i></b>, due to provider preference. <b style='color:DodgerBlue;'><i>Two</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>nine</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>IV</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>90</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>five</i></b> <b style='color:DodgerBlue;'><i>consecutive</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg/m(2)/day</i></b> <b style='color:MediumOrchid;'><i>temozolomide</i></b> <b style='color:DodgerBlue;'><i>IV</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>1.5</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>IV</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Median time to progression was 11 months. Median overall survival was 13 months. Objective tumor response at 3 months was 67 %, including six patients with partial response (PR) and three patients with stable disease (SD). At 6 months, objective response was 55 %, with two patients with PR and three with complete response. Additionally, one patient had SD and three had PD. Two patients remain alive and progression free at 15 and 55 months; another is alive with disease at 20 months. Toxicities included two patients with grade III neutropenia, two with grade III thrombocytopenia, one with grade III elevation of liver function tests, and one patient with grade III diarrhea. ### conclusions The combination of <b style='color:Tomato;'><i>bevacizumab</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b>, with or without <b style='color:Tomato;'><i>temozolomide</i></b>, produces objective responses with minimal toxicity in children with recurrent medulloblastoma. Prospective clinical trials are needed to evaluate the efficacy of this strategy.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Efficacy of  <span class="marker" data-anno-id="0" data-anno-label="P1/P2">tramadol</span>  in combination with  <span class="marker" data-anno-id="1" data-anno-label="P1">doxepin</span>  or  <span class="marker" data-anno-id="2" data-anno-label="P2">venlafaxine</span>  in inhibition of nociceptive process in the rat model of neuropathic pain : an isobolographic analysis . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Efficacy of  <span class="marker" data-anno-id="0" data-anno-label="P1/C1">tramadol</span>  in combination with  <span class="marker" data-anno-id="1" data-anno-label="P1">doxepin</span>  or  <span class="marker" data-anno-id="2" data-anno-label="C1">venlafaxine</span>  in inhibition of nociceptive process in the rat model of neuropathic pain : an isobolographic analysis . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>tramadol</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>doxepin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>venlafaxine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>nociceptive</i></b> <b style='color:DodgerBlue;'><i>process</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>rat</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>neuropathic</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>isobolographic</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Neuropathic pain constitutes a serious therapeutic problem. In most cases polytherapy is necessary. <b style='color:Tomato;'><i>tramadol</i></b> and antidepressants have common mechanisms of action and are frequently used together in clinical practice, thus interaction between them is very important. In the present study isobolographic analysis for equivalent doses of drugs was applied to examine the nature of interaction between <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>doxepin</i></b> or <b style='color:Tomato;'><i>venlafaxine</i></b> in a neuropathic pain model in rats. Allodynia and hyperalgesia were assessed after intraperitoneal administration of each drug alone or in combination. Dose response curves were obtained and ED(50) doses were calculated. All drugs were effective in reducing thermal hyperalgesia and mechanical allodynia, however <b style='color:Tomato;'><i>doxepin</i></b> was more effective than <b style='color:Tomato;'><i>venlafaxine</i></b>. Combined administration of <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>doxepin</i></b> demonstrated synergistic action in reducing thermal hyperalgesia and additive action in reducing mechanical allodynia. Combined administration of <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>venlafaxine</i></b> showed additive action in reducing hyperalgesia and allodynia. Moreover, combined administration of <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>doxepin</i></b> was more effective than combined administration of <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>venlafaxine</i></b>. The experiments demonstrated that the nature of interaction between <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>doxepin</i></b> is synergistic, which is not the case for <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>venlafaxine</i></b>, what provides a valuable information referring to clinical practice, rationalizing administration of such drug combination.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Patients with apical CFTR protein showed higher residual chloride secretion than those without ( amiloride to isoprenaline value of 4.59 and 0.56 mV , respectively , p = 0.01 ) . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Patients with apical CFTR protein showed higher residual chloride secretion than those without (  <span class="marker" data-anno-id="0" data-anno-label="P1">amiloride</span>  to  <span class="marker" data-anno-id="1" data-anno-label="P1">isoprenaline</span>  value of 4.59 and 0.56 mV , respectively , p = 0.01 ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Correlation between nasal potential difference measurements, genotype and clinical condition in patients with cystic fibrosis.</u></h4>In cystic fibrosis (CF), the clinical condition of patients correlates poorly with genotype. One possible explanation is that clinical status is influenced by net preserved chloride secretion rather than the CF mutation. We tested the relationships between residual chloride secretion, as measured by nasal potential difference (PD) and the type of mutation (genotypes expressing apical cystic fibrosis transmembrane conductance regulator (CFTR) protein versus those that do not) and clinical status. Twenty two CF patients (mean age 25.7 yrs, 11 females and 11 males, mean forced expiratory volume in one second (FEV1) 53.1% of predicted) with defined genotypes were recruited. Nasal PD was measured using a standard protocol involving the perfusion of the nasal epithelium with a sodium channel blocker (<b style='color:Tomato;'><i>amiloride</i></b>), followed by a solution of low chloride and finally with <b style='color:Tomato;'><i>isoprenaline</i></b>. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>apical</i></b> <b style='color:DodgerBlue;'><i>CFTR</i></b> <b style='color:DodgerBlue;'><i>protein</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>residual</i></b> <b style='color:DodgerBlue;'><i>chloride</i></b> <b style='color:DodgerBlue;'><i>secretion</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>amiloride</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>isoprenaline</i></b> <b style='color:DodgerBlue;'><i>value</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>4.59</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>0.56</i></b> <b style='color:DodgerBlue;'><i>mV</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>0.01</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> There was no correlation between mutation type and clinical condition. When these patients were recategorized as "high" (> 10 mV <b style='color:Tomato;'><i>amiloride</i></b> to <b style='color:Tomato;'><i>isoprenaline</i></b> response) or "low" (10 mV or less) chloride secretors, we found that the former group had a significantly higher FEV1 (67.7 versus 48.3% pred) and a better pulmonary radiological score (4.14 versus 7.07, by Northern scoring system). These results suggest that some cystic fibrosis patients, regardless of genotype, have an ability to secrete chloride when stimulated with chloride secretatagogues, and this is correlated with a better lung function. These results also have implications for the use of potential difference measurements in novel cystic fibrosis transmembrane conductance regulator replacement trials.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Comparison of the additive effects of  <span class="marker" data-anno-id="0" data-anno-label="P1">nipradilol</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P2">carteolol</span>  to  <span class="marker" data-anno-id="2" data-anno-label="P1/P2">latanoprost</span>  in open-angle glaucoma . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Comparison of the additive effects of  <span class="marker" data-anno-id="0" data-anno-label="C1">nipradilol</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">carteolol</span>  to  <span class="marker" data-anno-id="2" data-anno-label="C1/P1">latanoprost</span>  in open-angle glaucoma . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Comparison</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>additive</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>nipradilol</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carteolol</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>latanoprost</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>open-angle</i></b> <b style='color:DodgerBlue;'><i>glaucoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>To compare the effects of nipradilol and <b style='color:Tomato;'><i>carteolol</i></b> on intraocular pressure (IOP) when added to <b style='color:Tomato;'><i>latanoprost</i></b> treatment for glaucoma patients. ### methods Fifty patients with primary open-angle glaucoma were treated with <b style='color:Tomato;'><i>latanoprost</i></b> 0.005% once daily for 3 months. Then they were assigned to one of two groups randomly. One group received nipradilol 0.25% twice daily (nipradilol preceding group; n = 25), and the other <b style='color:Tomato;'><i>carteolol</i></b> hydrochloride 2% twice daily (<b style='color:Tomato;'><i>carteolol</i></b> preceding group; n = 25), for 3 months in addition to <b style='color:Tomato;'><i>latanoprost</i></b>. Then, nipradilol and <b style='color:Tomato;'><i>carteolol</i></b> were switched, and the subjects were treated for 3 more months. One eye was selected randomly for analysis. ### results In the nipradilol preceding group, IOP was 21.4 +/- 2.3 mmHg (mean +/- SD) at baseline, and 16.8 +/- 1.9 mmHg at the end of <b style='color:Tomato;'><i>latanoprost</i></b> monotherapy (P < 0.01). The addition of nipradilol decreased IOP to 15.8 +/- 1.7 mmHg, and the change to <b style='color:Tomato;'><i>carteolol</i></b>, to 15.3 +/- 2.0 mmHg. In the <b style='color:Tomato;'><i>carteolol</i></b> preceding group, IOP was 21.2 +/- 2.0 mmHg at baseline, and 17.0 +/- 2.1 mmHg at the end of <b style='color:Tomato;'><i>latanoprost</i></b> monotherapy (P < 0.01). The addition of <b style='color:Tomato;'><i>carteolol</i></b> decreased IOP to 15.4 +/- 1.8 mmHg, and the change to nipradilol, to 16.3 +/- 1.9 mmHg. Additional IOP reduction was greater with <b style='color:Tomato;'><i>carteolol</i></b> than with nipradilol (cross-over analysis of variance; P = 0.0005). ### conclusions Both nipradilol and <b style='color:Tomato;'><i>carteolol</i></b> have additive effects when used in combination with <b style='color:Tomato;'><i>latanoprost</i></b>. <b style='color:Tomato;'><i>carteolol</i></b>, however, may have a more potent effect than nipradilol.</div></div></div></div>

<script>
    var coll = document.getElementsByClassName("collapsible");
    var i;

    for (i = 0; i < coll.length; i++) {
        coll[i].addEventListener("click", function () {
            var content = this.nextElementSibling;
            console.log(content.style)
            if (content.style.display === "block") {
                content.style.display = "none";
            } else {
                content.style.display = "block";
            }
        });
    }
</script>
</body>

</html>